Showing results (1-10 of 573) with videos related to
Sort By:
Pageof 58
Acta Haematologica|August 7, 2023
Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management WorldwideStefano Molica, Marco Rossi, David AllsupHematological Oncology|April 29, 2025
Fixed Duration Ibrutinib-Venetoclax, a Redefinition of the CLL Treatment LandscapeStefano Molica, David AllsupMediterranean Journal of Hematology and Infectious Diseases|July 10, 2025
Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical ViewStefano Molica, David AllsupCancers|January 11, 2025
Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term SurvivorsStefano Molica, David AllsupCancers|September 27, 2025
Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapyStefano Molica, David AllsupExpert Review of Anticancer Therapy|November 28, 2023
Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trialsStefano Molica, David AllsupEuropean Journal of Haematology|March 12, 2026
Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) CareStefano Molica, David AllsupClinical Lymphoma, Myeloma & Leukemia|June 6, 2025
SOHO State of the Art Updates and Next Questions | The Evolving Landscape of Prognostic Models in Chronic Lymphocytic LeukemiaStefano Molica, Ahmad Ibrahim, David AllsupFrontiers in Oncology|April 24, 2023
An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapiesSujoy Khan, David Allsup, Stefano MolicaLeukemia & Lymphoma|June 21, 2026
An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysisStefano Molica, Diana Giannarelli, David AllsupPageof 58